Cargando…

Adjuvant chemotherapy in pathological node-negative non-small cell lung cancer

Non–small cell lung cancer (NSCLC) is associated with a poor survival rate, even for patients with early-stage cancer. Identifying patients with pathological N0 NSCLC who may benefit from adjuvant chemotherapy treatment after surgery is essential. We conducted a retrospective cohort study used data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Ya-Fu, Chen, Yi-Ling, Liu, Chia-Chi, Lin, Ching-Min, Tong, Shao-Syuan, Wang, Bing-Yen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628181/ https://www.ncbi.nlm.nih.gov/pubmed/37932436 http://dx.doi.org/10.1038/s41598-023-46679-8

Ejemplares similares

Prognostic Factors and the Role of Adjuvant Chemotherapy in Pathological Node-Negative T3 Gastric Cancer
por: Chen, Yi-Fu, et al.
Publicado: (2023)

Adjuvant Chemotherapy in Node-Negative Advanced Gastric Cancer Patients
por: Su, Jian-wei, et al.
Publicado: (2022)

Adjuvant Chemotherapy in Patients with Node-Negative Non-Small Cell Lung Cancer with Satellite Pulmonary Nodules in the Same Lobe
por: Park, Jiyoun, et al.
Publicado: (2022)

Adjuvant chemotherapy, not radiotherapy, prolongs survival for node-negative non–small cell lung cancer with positive surgical margins
por: Ashrafi, Arman, et al.
Publicado: (2023)

Association of Adjuvant Chemotherapy With Overall Survival Among Women With Small, Node-Negative, Triple-Negative Breast Cancer
por: Oladeru, Oluwadamilola T., et al.
Publicado: (2020)

Heterogeneous prognosis and adjuvant chemotherapy in pathological stage I non-small cell lung cancer patients
por: Liu, Chia-Hsin, et al.
Publicado: (2015)

Adjuvant Chemotherapy for Pathological Node-Positive Disease in Squamous Cell Carcinoma of the Esophagus after Neoadjuvant Chemoradiotherapy Plus Surgery
por: Lin, Jing-Wei, et al.
Publicado: (2022)

A phase III study of adjuvant chemotherapy in patients with completely resected, node-negative non–small cell lung cancer (JCOG 0707)
por: Kunitoh, Hideo, et al.
Publicado: (2020)

Analysis of Adjuvant Chemotherapy on Pathological Remission of Breast Cancer
por: Jiang, Bing, et al.
Publicado: (2021)

Adjuvant chemotherapy of non-small-cell lung cancer
por: Douillard, J.Y.
Publicado: (2013)

Adjuvant Chemotherapy of Non-Small Cell Lung Cancer
por: Pirker, Robert
Publicado: (2012)

The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer
por: Lim, Seung Taek, et al.
Publicado: (2018)

Prediction of Surgical Outcome by Tumor Volume Doubling Time via Stereo Imaging Software in Early Non-Small Cell Lung Cancer
por: Liu, Chia-Chi, et al.
Publicado: (2023)

A predictive model for identifying candidates for adjuvant chemotherapy based on recurrence risk profile of resected, node-negative (N0) non-small cell lung cancer
por: Krivitsky, Timur A., et al.
Publicado: (2021)

Lymph Node Parameters Predict Adjuvant Chemoradiotherapy Efficacy and Disease-Free Survival in Pathologic N2 Non-Small Cell Lung Cancer
por: Zhang, Chen-Chen, et al.
Publicado: (2021)

Effectiveness of adjuvant chemotherapy for elderly patients with triple-negative breast cancer
por: Guo, Qiusheng, et al.
Publicado: (2023)

The effect of adjuvant chemotherapy on survival in node negative colorectal cancer with or without perineural invasion: a systematic review and meta-analysis
por: Ying, Hongan, et al.
Publicado: (2023)

Efficacy of adjuvant chemotherapy on overall survival in patients with lymph node‐positive esophageal squamous cell carcinoma: Is oral chemotherapy promising?
por: Fang, Shuogui, et al.
Publicado: (2022)

Success Predictors of Adjuvant Chemotherapy in Node-Negative Breast Cancer Patients Under 55 years(1)
por: Janssen, Emiel A. M., et al.
Publicado: (2006)

Adjuvant chemotherapy for node negative, high Recurrence Score(TM) breast cancer: in defense of de-escalation
por: Lake, Diana, et al.
Publicado: (2019)

Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer
por: Lei, Tao, et al.
Publicado: (2016)

Reply to Graziosi et al. Rationale in the Use of Adjuvant Chemotherapy in pT3N0M0 Gastric Cancer Resected Patients. Comment on “Chen et al. Prognostic Factors and the Role of Adjuvant Chemotherapy in Pathological Node-Negative T3 Gastric Cancer. J. Pers. Med. 2023, 13, 553”
por: Chen, Yi-Fu, et al.
Publicado: (2023)

Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer
por: Yan, Shi, et al.
Publicado: (2010)

PTHrP, A Biomarker for CNS Metastasis in Triple-Negative Breast Cancer and Selection for Adjuvant Chemotherapy in Node-Negative Disease
por: Assaker, Gloria, et al.
Publicado: (2019)

A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status
por: Su, Ying-Wen, et al.
Publicado: (2018)

Size Measurement and Segmentectomy Resection Margin of Early-Stage Lung Adenocarcinoma Manifesting on Virtual 3D Imagery and Pathology: A Pilot Correlation Study
por: Lin, Ching-Min, et al.
Publicado: (2022)

Adjuvant chemotherapy may improve outcome of patients with non-small-cell lung cancer with metastasis of intrapulmonary lymph nodes after systematic dissection of N1 nodes
por: Wang, Xing, et al.
Publicado: (2018)

Is adjuvant chemotherapy better than neoadjuvant chemotherapy for those with node positive disease?
por: Zabell, Joseph, et al.
Publicado: (2018)

Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study
por: Batra, Atul, et al.
Publicado: (2020)

Adjuvant Chemotherapy for Early Stage Non-Small Cell Lung Cancer
por: Patel, Manali I., et al.
Publicado: (2011)

Is There a Role for Post-Mastectomy Radiotherapy for T1-2N1 Breast Cancers With Node-Positive Pathology After Patients Become Node-Negative Pathology Following Neoadjuvant Chemotherapy?
por: Wang, Qian, et al.
Publicado: (2020)

The not so small role of adjuvant chemotherapy in resected non-small cell lung cancer
por: Almquist, Daniel R., et al.
Publicado: (2021)

A prognostic and predictive computational pathology image signature for added benefit of adjuvant chemotherapy in early stage non-small-cell lung cancer
por: Wang, Xiangxue, et al.
Publicado: (2021)

Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population
por: Lim, SeungTaek, et al.
Publicado: (2015)

Adjuvant radiotherapy for patients with pathologic node‐negative esophageal carcinoma: A population based propensity matching analysis
por: Gao, Hui‐Jiang, et al.
Publicado: (2019)

Prognostic Value of Metastatic N1 Lymph Node Ratio and Angiolymphatic Invasion in Patients With Pathologic Stage IIA Non-Small Cell Lung Cancer
por: Wu, Ching-Feng, et al.
Publicado: (2014)

Sentinel Lymph Node Biopsy in Breast Cancer Patients Undergoing Neo-Adjuvant Chemotherapy: Clinical Experience with Node-Negative and Node-Positive Disease Prior to Systemic Therapy
por: Tinterri, Corrado, et al.
Publicado: (2023)

Ground Glass Opacity and Adjuvant Chemotherapy in Pathological Stage IB–IIA Lung Adenocarcinoma
por: Zhai, Wenyu, et al.
Publicado: (2022)

A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma
por: Ma, Xiaoling, et al.
Publicado: (2022)

Comparison of recurrence risk between patients with clinically node‐positive and ‐negative stage I non‐small cell lung cancer following surgery: A propensity score matching analysis
por: Huang, Kuo‐Yang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q48f3g7jb2i87lpu1uv529k19a